JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B
13th January 2025 Uncategorised 0Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that develops and markets products for the central nervous system.
More: JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for .6B
Source: fierce